Myriad Genetics (NASDAQ:MYGN) Stock Gets Price Target Boost from TD Cowen

Myriad Genetics (NASDAQ:MYGN) had its price objective hoisted by equities research analysts at TD Cowen from $4.50 to $6.75 in a research note issued on Thursday, Benzinga reports. The brokerage presently has a “hold” rating on the stock. TD Cowen‘s target price indicates a potential upside of 9.83% from the company’s current price.

Other analysts have also issued reports about the company. Zacks Research raised Myriad Genetics from a “strong sell” rating to a “hold” rating in a report on Thursday, October 15th. Stephens reduced their price objective on Myriad Genetics from $5.00 to $3.00 and set an “equal weight” rating for the company in a research note on Tuesday, August 18th. Leerink Partners lifted their target price on shares of Myriad Genetics from $5.00 to $8.00 and gave the stock a “market perform” rating in a research note on Thursday. Weiss Ratings cut shares of Myriad Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, October 27th. Finally, Wells Fargo & Company set a $4.50 target price on shares of Myriad Genetics in a report on Tuesday, October 20th. One research analyst has rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $5.55.

Myriad Genetics Stock Up 2.1%

MYGN traded up $0.13 on Thursday, hitting $6.15. The company had a trading volume of 2,492,419 shares, compared to its average volume of 1,896,531. The stock has a fifty day moving average price of $4.38 and a 200-day moving average price of $4.62. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.98 and a current ratio of 2.21. Myriad Genetics has a 12-month low of $2.74 and a 12-month high of $8.09. The stock has a market capitalization of $587.86 million, a price-to-earnings ratio of -5.19 and a beta of 1.62.

Myriad Genetics (NASDAQ:MYGN) last posted its earnings results on Wednesday, November 4th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.09. The company had revenue of $202.70 million during the quarter, compared to analysts’ expectations of $191.33 million. Myriad Genetics had a negative net margin of 13.96% and a negative return on equity of 16.09%. Analysts predict that Myriad Genetics will post -0.99 EPS for the current fiscal year.

Institutional Trading of Myriad Genetics

Hedge funds and other institutional investors have recently modified their holdings of the business. Orbimed Advisors LLC purchased a new stake in shares of Myriad Genetics in the 1st quarter valued at approximately $562,500,000. BlackRock Inc. purchased a new position in shares of Myriad Genetics in the 2nd quarter valued at about $62,184,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Myriad Genetics in the second quarter worth approximately $8,039,000. Man Group plc acquired a new position in Myriad Genetics during the 2nd quarter worth approximately $5,189,000. Finally, Bank of America Corp DE acquired a new position in Myriad Genetics during the 2nd quarter worth approximately $5,150,000. 99.02% of the stock is owned by institutional investors and hedge funds.

Key Myriad Genetics News

Here are the key news stories impacting Myriad Genetics this week:

• Positive Sentiment: Myriad reported Q3 revenue of $202.7 million, up 6% sequentially, and a loss of $0.11 per share—narrower than analysts’ expected $0.20 loss. Revenue also exceeded estimates. Read More.
• Positive Sentiment: The company raised the midpoint of its 2026 revenue guidance, citing execution and improved revenue per test. It also agreed to sell its Prenatal Health business for $210 million, a transaction Myriad says will support strategic growth initiatives. Read More.
• Neutral Sentiment: Q3 revenue was still 1% lower year over year, while test volume declined 2% year over year. Higher average revenue per test partly offset the volume weakness. Read More.
• Negative Sentiment: Myriad said it detected unauthorized access to its information technology systems on November 2 and is investigating whether data was accessed. Potential data exposure could create operational, legal, or reputational risks. Read More.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostics company that develops and provides genetic tests and related services to help healthcare providers assess disease risk, guide treatment decisions and support patient care. The company’s testing portfolio spans hereditary cancer, precision oncology, women’s health, mental health and other clinical applications.

Its products include hereditary cancer risk tests such as MyRisk and BRACAnalysis, which evaluate inherited genetic variants associated with cancers including breast and ovarian cancer.